ADHD is a recognized medical condition. It is classified as a neurodevelopmental disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the standard reference used by healthcare providers to diagnose mental health conditions. It also appears in the World Health Organization’s International Classification of Diseases. This isn’t a matter of opinion or debate within the medical community: a 2021 international consensus statement backed by leading ADHD researchers reviewed 208 evidence-based findings and concluded that misconceptions about ADHD stigmatize affected people and delay treatment.
What Makes ADHD a Medical Condition
A medical condition is generally defined by measurable biological differences, established diagnostic criteria, and evidence that it impairs normal functioning. ADHD checks all three boxes.
On the biological side, brain imaging studies show consistent structural differences between people with and without ADHD. A large mega-analysis published in The Lancet Psychiatry found reduced volumes in parts of the basal ganglia, a brain region involved in movement, motivation, and habit formation. These volume differences are most pronounced in children and tend to decrease with age, particularly among those who receive treatment.
At the chemical level, ADHD involves disrupted signaling between brain cells. The brain’s system for recycling dopamine, a chemical messenger tied to motivation, reward, and attention, works differently in people with ADHD. Transporters that clear dopamine from the spaces between neurons appear to function abnormally, which affects how signals travel through attention and reward circuits. A second chemical messenger, norepinephrine (involved in alertness and focus), is also implicated. The most effective ADHD medications work by increasing the availability of both these chemicals in the brain’s frontal regions.
The Genetic Component
ADHD runs in families, and twin studies consistently show it is one of the most heritable psychiatric conditions. In children, genetic factors account for roughly 70% to 80% of the risk. That figure drops to 30% to 40% in adult twin studies based on self-reported symptoms, though researchers believe this gap partly reflects differences in how adults recognize and report their own symptoms rather than a true decline in genetic influence.
No single gene causes ADHD. Most cases result from the combined effects of many genetic variants, each contributing a small amount of risk, interacting with environmental factors during development.
How ADHD Is Diagnosed
There is no blood test or brain scan used to diagnose ADHD in a clinical setting. Instead, healthcare providers follow structured criteria from the DSM-5. For children up to age 16, a diagnosis requires at least six symptoms of inattention, hyperactivity-impulsivity, or both. For teens 17 and older and adults, the threshold is five or more symptoms.
Beyond counting symptoms, several additional conditions must be met. Some symptoms need to have been present before age 12. The symptoms must show up in at least two different settings, such as home and work, or school and social situations. There must be clear evidence that the symptoms interfere with daily functioning. And the symptoms cannot be better explained by another condition like anxiety, depression, or a personality disorder.
This last point matters because many conditions mimic ADHD. Sleep deprivation or obstructive sleep apnea can produce a cognitive profile nearly identical to ADHD on testing. Depression causes concentration problems, irritability, and mental fog. Anxiety can look like inattention when a person’s mind is consumed by worry. A thorough evaluation distinguishes ADHD from these look-alikes, partly by checking whether attention problems persist even in calm, low-stress situations where anxiety isn’t a factor.
How Common ADHD Is
About 7 million U.S. children aged 3 to 17 have received an ADHD diagnosis at some point, according to 2022 survey data from the CDC. That translates to 11.4% of children in that age range. Rates vary significantly by state, ranging from 6% to 16%, which likely reflects differences in access to healthcare, screening practices, and diagnostic thresholds rather than true differences in how many children are affected.
ADHD persists into adulthood for the majority of people diagnosed in childhood, though symptoms often shift. Hyperactivity tends to become less visible, while difficulties with organization, time management, and sustained focus may become more prominent as life demands increase.
What Happens Without Treatment
Untreated ADHD carries real health consequences. A 2025 study from University College London found that adults with diagnosed ADHD had reduced life expectancies: between 4.5 and 9 fewer years for men, and between 6.5 and 11 fewer years for women. The researchers could not pinpoint exact causes of death, but ADHD is associated with higher rates of accidental injury, substance use, and mental health problems, all of which contribute to earlier mortality.
The World Federation of ADHD’s consensus statement notes that untreated ADHD costs society hundreds of billions of dollars each year worldwide, through lost productivity, healthcare costs, and involvement with the criminal justice system. Treatment and support are associated with better outcomes across the board, including reduced substance use and fewer mental health complications.
How Treatment Works
ADHD medications target the dopamine and norepinephrine systems described earlier, increasing the availability of these chemical messengers in the brain’s attention networks. A 2024 meta-analysis found that all three major medication classes improved quality of life compared to placebo, with moderate effect sizes. Behavioral strategies, including organizational coaching, cognitive behavioral therapy, and environmental modifications like reducing distractions, are often used alongside medication or on their own for people who prefer a non-medication approach.
Treatment doesn’t eliminate ADHD, but it can substantially reduce the gap between a person’s capabilities and their daily functioning. The brain imaging research supports this: stimulant treatment was associated with basal ganglia volumes closer to those seen in people without ADHD, suggesting that medication may help normalize some of the structural differences linked to the condition.